VERUVeru Inc
Mkt Cap
$55.7MVolume
0.0052W High
$14.2052W Low
$2.64PE Ratio
-1.95VERU Fundamentals
50D MA
$3.71Beta
0.61Avg. Volume
143,886.62EPS (Annual)
-$2.80P/B
3.63Rev/Employee
$80,411.52Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
210
Frequently Asked Questions
What is Market Cap of Veru Inc?
What is the 52-week high for Veru Inc?
What is the 52-week low for Veru Inc?
What is the PE ratio of Veru Inc?
What is the Price-to-Book ratio of Veru Inc?
What is the 50-day moving average of Veru Inc?
How many employess does Veru Inc has?